Mobile

A double-blind, placebo controlled, randomised, parallel group, single centre, phase IIa study to investigate the efficacy, tolerability and safety of 8 doses of AZD8848 administered intranasally once...

Mise à jour : Il y a 4 ans
Référence : EUCTR2009-013705-34

A double-blind, placebo controlled, randomised, parallel group, single centre, phase IIa study to investigate the efficacy, tolerability and safety of 8 doses of AZD8848 administered intranasally once weekly in mild to moderate allergic asthma patients challenged with an inhaled allergen

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

To evaluate the efficacy of AZD8848 on the Late Asthmatic Response (LAR) compared with placebo after 8 doses of once weekly intranasal administration in mild to moderate asthma patients challenged with inhaled allergen (Main Part only).

Critère d'inclusion

  • Allergic asthma

Liens